Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab.
Federico InnocentiAkram YazdaniNaim RashidXueping QuFang-Shu OuScott Van BurenMonica M BertagnolliOmar KabbarahCharles David BlankeAlan P VenookHeinz-Josef LenzBenjamin G VincentPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
New immune features can be further evaluated to improve patient response. They provide the rationale for more effective immunotherapy strategies.